Vinci Pharmaceuticals is a specialty ophthalmic pharmaceutical company based in Avon-by-the-Sea, New Jersey, developing first-, best- and only-in-class therapies for diseases of the retina. Its proprietary EPIPLANT platform is an episcleral, needle-free sustained-release drug delivery implant designed to address the limitations of repeated intraocular injections, with lead product candidate VCI-002. The technology was developed in the laboratory of Karl Csaky, MD, PhD, and licensed from the Retina Foundation of the Southwest, and the company is preparing a first-in-human Phase 1/2a study in 2027.
1
Round
1
Industry
5
Tags
Oct 8, 2026
Latest raise
Funding activity · 1 round
Oct 8, 2026
$8M
Series A
Led by Dynagrow Capital
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
